Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma.

Dinh A, Palmer MB, Svoboda J, Hogan JJ.

Leuk Lymphoma. 2019 May 24:1-3. doi: 10.1080/10428194.2019.1616187. [Epub ahead of print] No abstract available.

PMID:
31125280
2.

Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.

Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC.

Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30050-X. doi: 10.1016/j.kint.2019.01.009. [Epub ahead of print]

PMID:
30910380
3.

Native kidney BK virus nephropathy, a systematic review.

Shah A, Kumar V, Palmer MB, Trofe-Clark J, Laskin B, Sawinski D, Hogan JJ.

Transpl Infect Dis. 2019 Mar 25:e13083. doi: 10.1111/tid.13083. [Epub ahead of print] Review.

PMID:
30907978
4.

DNMT1 in Six2 Progenitor Cells Is Essential for Transposable Element Silencing and Kidney Development.

Li SY, Park J, Guan Y, Chung K, Shrestha R, Palmer MB, Susztak K.

J Am Soc Nephrol. 2019 Apr;30(4):594-609. doi: 10.1681/ASN.2018070687. Epub 2019 Mar 8.

PMID:
30850438
5.

Characterization of a new physical phantom for testing rigid and deformable image registration.

Wu RY, Liu AY, Wisdom P, Zhu XR, Frank SJ, Fuller CD, Gunn GB, Palmer MB, Wages CA, Gillin MT, Yang J.

J Appl Clin Med Phys. 2019 Jan;20(1):145-153. doi: 10.1002/acm2.12514. Epub 2018 Dec 23.

6.

The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care.

Ning MS, Gomez DR, Shah AK, Kim CR, Palmer MB, Thaker NG, Grosshans DR, Liao Z, Chapman BV, Brooks ED, Tang C, Rosenthal DI, Garden AS, Frank SJ, Gunn GB.

Int J Radiat Oncol Biol Phys. 2018 Dec 14. pii: S0360-3016(18)34185-3. doi: 10.1016/j.ijrobp.2018.12.019. [Epub ahead of print]

PMID:
30557675
7.

Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Babushok DV, Nelson EJ, Morrissette JJD, Joshi S, Palmer MB, Frank D, Cambor CL, Hexner EO.

Leuk Lymphoma. 2019 Mar;60(3):852-855. doi: 10.1080/10428194.2018.1509319. Epub 2018 Sep 19. No abstract available.

PMID:
30227762
8.

A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

Gumber R, Cohen JB, Palmer MB, Kobrin SM, Vogl DT, Wasserstein AG, Nasta SD, Bleicher MB, Bloom RD, Dember L, Cohen A, Weiss BM, Hogan JJ.

Kidney Int. 2018 Jul;94(1):199-205. doi: 10.1016/j.kint.2018.02.020. Epub 2018 May 11.

PMID:
29759418
9.

Frameshifts in Code and in Care: The Importance of Timely Genetic Evaluation.

Reza N, Chowns JL, Merrill SL, Marzolf A, Zado ES, Palmer MB, Deshpande C, Pryma DA, Rame JE, Marchlinski FE, Owens AT.

Circ Genom Precis Med. 2018 May;11(5):e002215. doi: 10.1161/CIRCGEN.118.002215. No abstract available.

PMID:
29748321
10.

Reproducibility and Feasibility of Strategies for Morphologic Assessment of Renal Biopsies Using the Nephrotic Syndrome Study Network Digital Pathology Scoring System.

Zee J, Hodgin JB, Mariani LH, Gaut JP, Palmer MB, Bagnasco SM, Rosenberg AZ, Hewitt SM, Holzman LB, Gillespie BW, Barisoni L.

Arch Pathol Lab Med. 2018 May;142(5):613-625. doi: 10.5858/arpa.2017-0181-OA. Epub 2018 Feb 19.

11.

Examining the Link between Biofilm Formation and the Ability of Pathogenic Salmonella Strains to Colonize Multiple Host Species.

MacKenzie KD, Palmer MB, Köster WL, White AP.

Front Vet Sci. 2017 Aug 25;4:138. doi: 10.3389/fvets.2017.00138. eCollection 2017. Review.

12.

ARF6 mediates nephrin tyrosine phosphorylation-induced podocyte cellular dynamics.

Lin JS, Jeon JS, Fan Q, Wong HN, Palmer MB, Holzman LB.

PLoS One. 2017 Sep 7;12(9):e0184575. doi: 10.1371/journal.pone.0184575. eCollection 2017.

13.

Increasing the level of peroxisome proliferator-activated receptor γ coactivator-1α in podocytes results in collapsing glomerulopathy.

Li SY, Park J, Qiu C, Han SH, Palmer MB, Arany Z, Susztak K.

JCI Insight. 2017 Jul 20;2(14). pii: 92930. doi: 10.1172/jci.insight.92930. eCollection 2017 Jul 20.

14.

New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy
.

Ghosn M, Palmer MB, Najem CE, Haddad D, Merkel PA, Hogan JJ.

Clin Nephrol. 2017 May;87 (2017)(5):261-266. doi: 10.5414/CN109019.

PMID:
28332476
15.

Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K.

Nat Med. 2017 Apr;23(4):429-438. doi: 10.1038/nm.4287. Epub 2017 Feb 20.

16.

Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection.

Hogan JJ, Lim MA, Palmer MB, Bloom RD, Chung RT, Sise ME.

Hepatology. 2017 Aug;66(2):658-660. doi: 10.1002/hep.29125. Epub 2017 Jun 22. No abstract available.

PMID:
28211090
17.

Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.

Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park AS, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K, Verma A, Susztak K.

J Biol Chem. 2017 Jan 20;292(3):837-846. doi: 10.1074/jbc.M116.745208. Epub 2016 Dec 1.

18.

Quantitative analysis of treatment process time and throughput capacity for spot scanning proton therapy.

Suzuki K, Palmer MB, Sahoo N, Zhang X, Poenisch F, Mackin DS, Liu AY, Wu R, Zhu XR, Frank SJ, Gillin MT, Lee AK.

Med Phys. 2016 Jul;43(7):3975. doi: 10.1118/1.4952731.

PMID:
27370116
19.

Proteasome inhibitor associated thrombotic microangiopathy.

Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D'Agati VD, Kastritis E, Dimopoulos MA, Vij R, Bansal D, Dingli D, Nasr SH, Leung N.

Am J Hematol. 2016 Sep;91(9):E348-52. doi: 10.1002/ajh.24447. Epub 2016 Jul 4.

20.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

21.

Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome.

Castano E, Palmer MB, Vigneault C, Luciano R, Wong S, Moeckel G.

BMC Nephrol. 2015 Apr 29;16:64. doi: 10.1186/s12882-015-0046-0.

22.

Quantification and localization of M2 macrophages in human kidneys with acute tubular injury.

Palmer MB, Vichot AA, Cantley LG, Moeckel GW.

Int J Nephrol Renovasc Dis. 2014 Nov 7;7:415-9. doi: 10.2147/IJNRD.S66936. eCollection 2014.

23.

Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.

McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):819-27. doi: 10.1016/j.ijrobp.2014.07.030. Epub 2014 Sep 11.

PMID:
25220718
24.

Estimated risk of radiation-induced cancer following paediatric cranio-spinal irradiation with electron, photon and proton therapy.

Stokkevåg CH, Engeseth GM, Ytre-Hauge KS, Röhrich D, Odland OH, Muren LP, Brydøy M, Hysing LB, Szostak A, Palmer MB, Petersen JB.

Acta Oncol. 2014 Aug;53(8):1048-57. doi: 10.3109/0284186X.2014.928420. Epub 2014 Jul 14.

PMID:
25017376
25.

Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice.

Frank SJ, Cox JD, Gillin M, Mohan R, Garden AS, Rosenthal DI, Gunn GB, Weber RS, Kies MS, Lewin JS, Munsell MF, Palmer MB, Sahoo N, Zhang X, Liu W, Zhu XR.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):846-53. doi: 10.1016/j.ijrobp.2014.04.019. Epub 2014 May 24.

26.

Proton beam therapy for the treatment of prostate cancer.

Pugh TJ, Choi S, Nguyen QN, Gillin MT, Ron Zhu X, Palmer MB, Lee AK.

Pract Radiat Oncol. 2013 Apr-Jun;3(2):e87-94. doi: 10.1016/j.prro.2012.05.010. Epub 2012 Jul 12. Review.

PMID:
24674325
27.

Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer.

McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR.

Radiother Oncol. 2013 Oct;109(1):38-44. doi: 10.1016/j.radonc.2013.08.014. Epub 2013 Sep 7.

PMID:
24016675
28.

Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: Robustness analysis through simulation of rotational and translational alignment errors.

Pugh TJ, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, Palmer MB, Lee AK.

Med Dosim. 2013 Autumn;38(3):344-50. doi: 10.1016/j.meddos.2013.03.007. Epub 2013 Jun 6.

29.

Generalizable class solutions for treatment planning of spinal stereotactic body radiation therapy.

Weksberg DC, Palmer MB, Vu KN, Rebueno NC, Sharp HJ, Luo D, Yang JN, Shiu AS, Rhines LD, McAleer MF, Brown PD, Chang EL.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):847-53. doi: 10.1016/j.ijrobp.2011.12.060. Epub 2012 Mar 22.

PMID:
22445000
30.

Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma.

Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, Krishnan S, Das P.

Radiat Oncol. 2011 Jun 8;6:63. doi: 10.1186/1748-717X-6-63.

31.

Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.

Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1336-42. doi: 10.1016/j.ijrobp.2010.07.2001. Epub 2011 Apr 4.

32.

Esophageal cancer dose escalation using a simultaneous integrated boost technique.

Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):468-74. doi: 10.1016/j.ijrobp.2010.10.023. Epub 2010 Dec 1.

33.

Yin yang 1 regulates the expression of snail through a distal enhancer.

Palmer MB, Majumder P, Cooper JC, Yoon H, Wade PA, Boss JM.

Mol Cancer Res. 2009 Feb;7(2):221-9. doi: 10.1158/1541-7786.MCR-08-0229. Epub 2009 Feb 10.

34.

A 3' enhancer controls snail expression in melanoma cells.

Palmer MB, Majumder P, Green MR, Wade PA, Boss JM.

Cancer Res. 2007 Jul 1;67(13):6113-20.

35.

Cotton genome mapping with new microsatellites from Acala 'Maxxa' BAC-ends.

Frelichowski JE Jr, Palmer MB, Main D, Tomkins JP, Cantrell RG, Stelly DM, Yu J, Kohel RJ, Ulloa M.

Mol Genet Genomics. 2006 May;275(5):479-91. Epub 2006 Feb 25.

PMID:
16501995
36.

Chromosomal regulation by MeCP2: structural and enzymatic considerations.

Bowen NJ, Palmer MB, Wade PA.

Cell Mol Life Sci. 2004 Sep;61(17):2163-7. Review.

PMID:
15338046
37.

Comparison of three brachytherapy gynecological intercavitary treatment planning systems.

Concannon PJ, Mermis N, Nguyen L, Palmer MB.

Med Dosim. 2004 Summer;29(2):115-7.

PMID:
15191758
38.

Methods for preparation and assays for Xenopus ISWI complexes.

Palmer MB, Elgar S, Wade PA.

Methods Enzymol. 2004;377:364-75. No abstract available.

PMID:
14979038
39.

Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer.

Lee HK, D'Souza WD, Yamal JM, Pollack A, Lee AK, Palmer MB, Kuban DA.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):355-61.

PMID:
12957245
40.

Is intraoperative nomogram-based overplanning of prostate implants necessary?

D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):462-7.

PMID:
12738321
41.

Fertility, hatchability and progeny performance of laying hens fed high levels of DDT in the diet.

Britton WM, Palmer MB, Howarth B Jr.

Poult Sci. 1974 May;53(3):1053-5. No abstract available.

PMID:
4841693
42.

The requirement of a trypsin-like acrosomal enzyme for fertilization in the domestic fowl.

Palmer MB, Howarth B Jr.

J Reprod Fertil. 1973 Oct;35(1):7-11. No abstract available.

PMID:
4742167
43.

An examination of the need for sperm capacitation in the turkey, Meleagris gallopavo.

Howarth B Jr, Palmer MB.

J Reprod Fertil. 1972 Mar;28(3):443-5. No abstract available.

PMID:
5014341
44.

A STUDY OF THE MEMBERSHIP AND PROGRAM OF A CLUB FOR EXPATIENTS OF MENTAL HOSPITALS.

PALMER MB, HOFFMAN EL.

Ment Hyg. 1964 Jul;48:372-9. No abstract available.

PMID:
14172418
45.

Social rehabilitation for mental patients.

PALMER MB.

Ment Hyg. 1958 Jan;42(1):24-8. No abstract available.

PMID:
13503660

Supplemental Content

Loading ...
Support Center